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Introduction: This post hoc analysis of the “Early MAXimization of bronchodilation for 
improving COPD stability” (EMAX) trial investigated whether patients achieving early 
clinically important improvement (CII) sustained longer-term improvements and lower risk 
of clinically important deterioration (CID).
Methods: Patients were randomized to umeclidinium/vilanterol, umeclidinium, or salmeterol for 
24 weeks. The patient-reported outcomes (PROs) Transition Dyspnea Index (TDI), Evaluating 
Respiratory Symptoms, St George’s Respiratory Questionnaire (SGRQ) and COPD Assessment 
Test (CAT) were assessed. CII, defined as attaining minimum clinically important differences 
(MCID) in ≥2 PROs, was assessed at Weeks 4, 12 and 24. CID was defined as a deterioration in 
CAT, SGRQ, TDI by the MCID and/or a moderate/severe exacerbation from Day 30.
Results: Of 2425 patients, 50%, 53% and 51% achieved a CII at Weeks 4, 12 and 24, respectively. 
Patients with a CII at Week 4 versus those without had significantly greater odds of achieving a CII 
at Weeks 12 and 24 (odds ratio: 5.57 [95% CI: 4.66, 6.66]; 4.09 [95% CI: 3.44, 4.86]). The risk of 
a CID was higher in patients who did not achieve a CII at Week 4 compared with patients who did 
(hazard ratio [95% CI]: 2.09 [1.86, 2.34]). Patients treated with umeclidinium/vilanterol versus 
either monotherapy had significantly greater odds of achieving CII at Weeks 4, 12 and 24.
Conclusion: Achieving a CII at Week 4 was associated with longer-term improvement in 
PROs and a reduced risk of deterioration. Further research is required to investigate the 
importance of an early response to treatment on the long-term disease course.
Keywords: bronchodilator, clinically important improvement, clinically important 
deterioration, COPD symptoms, early improvement, patient-reported outcomes
Plain Language Summary
Why Was The Study Done?
For patients with chronic obstructive pulmonary disease (COPD) it is important to monitor 
changes in their disease in response to treatment. Patient-reported outcomes (PROs) are 
assessments completed by patients to measure changes in their symptoms or well-being.
We aimed to understand whether improvements in COPD after 4 weeks of treatment 
indicate whether patients will have longer-term benefits from that treatment.
What Did Researchers Do/Find?
The “Early MAXimization of bronchodilation for improving COPD stability” (EMAX) trial 
compared treatment with umeclidinium/vilanterol, umeclidinium and salmeterol in patients 
with COPD over 24 weeks.
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Patients completed four PROs, which were analyzed to see if 
changes in their symptoms and well-being had a noticeable 
impact on their daily life. Patients who reached a threshold of 
improvement in at least two PROs were considered to have 
achieved a clinically important improvement (CII).
At Week 4, 1211 (50%) patients had a CII and 1211 patients 
did not. Patients who had a CII at Week 4 were over 4 times 
more likely to have a CII at Week 24 than patients without a CII 
at Week 4. They were also less likely to have a deterioration in 
their COPD over the remaining duration of the trial.
More patients treated with umeclidinium/vilanterol had a CII 
compared with patients treated with umeclidinium or salmeterol.
What Do These Results Mean?
Early assessment of CII may indicate which patients are more 
likely to have longer-term benefit from a treatment. This may 
help enable quicker optimization of a patient’s treatment.
Introduction
Chronic obstructive pulmonary disease (COPD) is usually 
a progressive condition with declining lung function often 
occurring in the early stages of the disease.1–3 Therefore, it is 
important to optimize maintenance treatment early in the 
disease course.4 It has been established that bronchodilators 
improve lung function and symptomatic outcomes,5 and 
reduce the risk of a clinically important deterioration 
(CID).6–11 However, it is not known whether patients with 
an early clinically relevant improvement in disease outcomes 
in response to treatment also experience longer-term clinical 
improvements and have a lower risk of disease worsening. 
This information may aid earlier treatment decisions and 
support timely adjustments in medication.
The impact of COPD on patients is wide-ranging and 
multiple patient-reported outcomes (PROs) have been devel-
oped to assess different aspects of the disease, including 
breathlessness, symptoms and health status. Therefore, 
assessment of multiple PROs may be required to identify 
patients who have a response to treatment. Consequently, the 
use of a composite endpoint called “clinically important 
improvement” (CII) has been proposed to assess positive 
treatment responses. In a post hoc analysis of the FLAME 
study in symptomatic patients at risk of an exacerbation, 
a CII composite endpoint was defined as the achievement of 
a ≥100 mL increase in trough forced expiratory volume in 
1 second (FEV1) and a minimally CII on the COPD 
Assessment Test (CAT) or St George’s Respiratory 
Questionnaire (SGRQ) at 4 or 12 weeks after treatment 
initiation.12 Although only 18–20% of patients achieved 
this CII endpoint, the achievement of this CII at 4 weeks 
was associated with a minor signal for a reduced risk of 
future exacerbations. Given the low CII response rates in the 
FLAME study,12 a population with less severe disease, not 
enriched for an exacerbation history and not already using 
combination therapy may be more suitable for generating 
evidence in support of the CII concept.
The “Early MAXimization of bronchodilation for 
improving COPD stability” (EMAX) trial enrolled sympto-
matic patients with COPD who were not receiving inhaled 
corticosteroid (ICS) either at baseline or concurrently during 
the study treatment period and were at low risk of 
exacerbations.13 The study demonstrated that over 24 
weeks, umeclidinium/vilanterol (UMEC/VI) consistently 
provided greater lung function and symptom improvements 
versus UMEC and salmeterol (SAL) monotherapy, with sig-
nificant treatment differences identified as early as 4 weeks 
after treatment initiation.13
We hypothesized that patients with COPD who achieve 
a minimum clinically important difference (MCID) in two or 
more PROs 4 weeks after treatment initiation are more likely 
to continue to show positive PRO treatment responses over 
24 weeks than those with MCIDs in fewer than two PROs. 
To assess this, we conducted a post hoc analysis of the 
EMAX trial and describe a novel CII composite endpoint 
that requires MCIDs in at least two PRO measures. 
Additionally, it was investigated if patients who achieved 
an early CII also had an improvement in perceived disease 
severity and a reduced risk of disease worsening.
Materials and Methods
Study Design, Patients and Outcomes
EMAX (NCT03034915; GSK study 201749) was 
a multicenter, double-blind, double-dummy, 3-arm paral-
lel-group study conducted between June 2017 and 
June 2018. Patients were randomized 1:1:1 to UMEC/VI 
62.5/25 µg once daily via the ELLIPTA inhaler and twice- 
daily placebo via the DISKUS inhaler, once-daily UMEC 
(62.5 µg) via ELLIPTA and twice-daily placebo via 
DISKUS, or twice-daily SAL (50 µg) via DISKUS and 
once-daily placebo via ELLIPTA for 24 weeks.13 The 
study design and methods have been published 
previously.13 Briefly, patients were outpatients at study 
entry, ≥40 years of age with a diagnosis of COPD, had 
a FEV1/forced vital capacity (FVC) ratio <0.7, a post- 
salbutamol FEV1 of ≥30–≤80% predicted, a CAT score 
≥10, and ≤1 moderate exacerbation (requiring oral or 
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systemic corticosteroids and/or antibiotics) and no severe 
exacerbations (requiring hospitalization) in the 
previous year. Prior to the 4-week run-in period, patients 
were required to be ICS-free for ≥6 weeks and long-acting 
muscarinic antagonist/long-acting β2-agonist (LAMA/ 
LABA)-free for ≥2 weeks. Salbutamol was permitted 
throughout the study as needed. This study was performed 
according to the Declaration of Helsinki and received 
appropriate ethical approval (Supplementary File 1). All 
patients provided written informed consent at either the 
pre-Screening or Screening visit.
In this post hoc analysis, change from baseline in trough 
FEV1 and the proportion of responders for trough FEV1, 
self-administered computerized-Transition Dyspnea Index 
(SAC-TDI), SGRQ and CAT were assessed at Weeks 4, 12 
and 24; Evaluating Respiratory Symptoms: COPD (E-RS) 
was assessed at Weeks 1–4, 9–12 and 21–24. MCID 
responses were defined as achieving ≥100 mL increase 
from baseline in trough FEV1,14 ≥1-unit improvement 
from baseline (Baseline Dyspnea Index; BDI) in SAC-TDI 
score,15 ≥2-point reduction from baseline in E-RS total 
score,16 ≥4-point reduction from baseline in SGRQ 
score,17 and ≥2-unit reduction from baseline in CAT 
score.18 A CII response was defined as a MCID response 
in at least two of the SAC-TDI, E-RS, SGRQ and CAT 
endpoints at the same time point. Global Assessment of 
Disease Severity (GADS) was rated by patients at baseline 
(“Mild”, “Moderate”, “Severe”, “Very Severe”), and change 
in severity from baseline was rated at Week 4 on a 7-point 
Likert scale (“Much Better”, “Better”, “Slightly Better”, 
“No Change”, “Slightly Worse”, “Worse”, “Much Worse”). 
The occurrence of moderate/severe exacerbations and CID, 
defined as a first moderate or severe exacerbation, and/or a 
SGRQ deterioration (≥4 unit increase from baseline), and/or 
a CAT deterioration (≥2 unit increase from baseline), and/or 
a SAC-TDI deterioration (≥1 unit decrease from baseline), 
were assessed after Day 30 until Week 24.
Statistical Analysis
All analyses of CII were performed post hoc for the intent-to- 
treat (ITT) population, which comprised all patients who 
were randomized and received ≥1 dose of study treatment. 
Treatment groups were pooled for analyses comparing 
patients who did and did not achieve a CII at Week 4. 
A comparison of baseline characteristics was performed for 
patients with versus without a CII at Week 4; means for 
continuous variables were compared with a t-test, and pro-
portions for categorical variables were compared with 
a Fisher’s Exact Test. The odds of a patient achieving a CII 
response was calculated using generalized linear mixed mod-
els with treatment as an explanatory variable and visit, base-
line SGRQ score, baseline CAT score, BDI focal score, 
baseline E-RS score, geographical region, number of bronch-
odilators per day during run-in, visit by baseline SGRQ 
score, visit by baseline CAT score, visit by BDI focal score, 
visit by baseline E-RS score and visit by treatment interac-
tions included as covariates. The odds of a patient achieving 
CII at Weeks 12 and 24 by the achievement or non- 
achievement of CII at Week 4 were calculated using general-
ized linear models with covariates of number of PRO 
responses at Week 4 (<2 or ≥2), visit, treatment, number of 
bronchodilators per day during run-in, geographical region, 
visit by treatment and visit by number of PRO responses at 
Week 4 interactions. Ordered odds ratios (OR) of a better 
GADS response category were calculated using generalized 
linear models with covariates of the number of PRO 
responses, treatment, number of bronchodilators per day dur-
ing run-in and geographical region. The hazard ratio (HR) for 
a CID was calculated using a Cox proportional hazards 
model with covariates of CII at Week 4, treatment, number 
of bronchodilators per day during run-in, geographical 
region, baseline CAT score, baseline SGRQ score and SAC- 
BDI focal score. The number of patients who needed to be 
treated (NNT) for one additional patient to achieve a CII was 
calculated for UMEC/VI versus either monotherapy at 
Week 24.
Results
Patient Demographics and Baseline 
Characteristics
A total of 2425 (UMEC/VI N=812; UMEC N=804; SAL 
N=809) patients were included in the ITT population 
(Table 1). Half of the patients were current smokers and 
16% had experienced a moderate COPD exacerbation 
within the previous year. BDI, baseline E-RS, CAT and 
SGRQ scores and the distribution of GADS response 
categories were similar across treatment groups.
Association Between Achieving a CII at 
Week 4 and Other Outcomes
Baseline Characteristics
At Week 4, 79%, 50%, 26% and 8% of patients were respon-
ders to at least 1, 2, 3 or 4 PROs, respectively. Patients 
achieved a CII (at least 2 PRO responses) at Week 4 with 
several different combinations of PRO responses, with 
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a greater proportion of patients achieving a CAT or SAC-TDI 
response and a smaller proportion achieving an E-RS or 
SGRQ response (Supplementary Figure 1).
Patients who achieved a CII at Week 4 had signifi-
cantly greater percent reversibility to salbutamol, mean 
baseline rescue medication use, E-RS score, CAT score 
and SGRQ total score and a significantly smaller propor-
tion of patients were receiving a long-acting bronchodila-
tor at baseline compared with those without a CII at Week 
4 (Table 2). More patients with a CII at Week 4 rated their 
COPD as moderate or severe at baseline, compared with 
patients without a CII.
Achieving a CII at Weeks 12 and 24
Overall, 50%, 53% and 51% of patients in the ITT popula-
tion achieved a CII at Weeks 4, 12 and 24, respectively. 
Patients achieving a CII at Week 4 were more than 5-fold 
more likely to be responders at Week 12 and 4-fold more 
likely to be responders at Week 24 compared with patients 
who did not achieve a CII at Week 4 (both p<0.001) 
(Figure 1).
Patients’ Global Assessment of Disease Severity
The proportion of patients reporting a GADS of “Slightly 
Better”, “Better” or “Much Better” at Week 4 was greater for 
patients who achieved a CII at Week 4 (n=955/1210; 79%) 
compared with those who did not (n=417/1100; 38%), and 
increased in parallel with the number of PRO responses 
(Table 3). Furthermore, patients who achieved a CII at 
Week 4 had a significantly higher ordered OR of an improve-
ment in GADS at Week 4 versus those who did not achieve 
a CII at Week 4 (p<0.001). Patients with 1, 2, 3 or 4 PRO 
responses at Weeks 4 also had significantly higher ordered 
ORs of an improvement in GADS at Week 4 versus those 
Table 1 Patient Demographics and Baseline Characteristics
Characteristic UMEC/VI (N=812) UMEC (N=804) SAL (N=809) Total (N=2425)
Age, years, mean (SD) 64.6 (8.4) 64.9 (8.5) 64.4 (8.5) 64.6 (8.5)
Female, n (%) 319 (39) 327 (41) 342 (42) 988 (41)
Current smoker at screening, n (%) 394 (49) 396 (49) 413 (51) 1203 (50)
Moderate COPD exacerbation in prior yeara, n (%) 123 (15) 124 (15) 146 (18) 393 (16)
Duration of COPD, years, mean (SD) 8.8 (6.9) 7.8 (6.0) 8.3 (6.7) 8.3 (6.6)
Use of a bronchodilator during run in, n (%) 531 (65) 521 (65) 524 (65) 1576 (65)
GOLD spirometric gradeb, n (%)
2 518 (64) 529 (66) 522 (65) 1569 (65)
3 294 (36) 271 (34) 286 (35) 851 (35)
Post salbutamol % predicted FEV1, mean (SD) 54.9 (12.8) 55.9 (12.6) 55.6 (12.8) 55.4 (12.7)
% reversibility to salbutamol, mean (SD) 10.4 (12.8) 10.2 (13.3) 10.7 (13.3) 10.5 (13.1)
GADS, n (%)
Mild 136 (17) 139 (17) 136 (17) 411 (17)
Moderate 558 (69) 549 (68) 565 (70) 1672 (69)
Severe 112 (14) 108 (13) 100 (12) 320 (13)
Very severe 5 (<1) 6 (<1) 8 (<1) 19 (<1)
BDI score, mean (SD) 7.0 (1.8) 7.0 (1.9) 7.1 (1.8) 7.0 (1.9)
E-RS total score, mean (SD) 10.7 (5.6) 10.7 (5.8) 10.4 (5.7) 10.6 (5.7)
SGRQ score, mean (SD) 44.5 (16.1) 45.0 (16.1) 44.6 (16.3) 44.7 (16.2)
CAT score, mean (SD) 19.1 (5.9) 19.3 (6.2) 19.3 (6.3) 19.2 (6.1)
Notes: aNumber of exacerbations requiring oral or systemic corticosteroids and/or antibiotics (moderate) in 12 months prior to screening (patients with >1 moderate 
exacerbation or with a severe exacerbation [requiring hospitalization] were excluded); ban additional 4 (<1%) patients with GOLD grade 1 were randomized (UMEC n=3; 
SAL n=1). 
Abbreviations: BDI, Baseline Dyspnea Index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms: 
COPD; FEV1, forced expiratory volume in 1 second; GADS, Global Assessment of Disease Severity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SAL, 
salmeterol; SD, standard deviation; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.
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with zero PRO responses at Week 4 (all p<0.001) and the 
magnitude of the ordered ORs was greater for patients with 
a higher number of PRO responses (Table 4).
Clinically Important Deterioration
Among patients achieving a CII at Week 4, 45% experi-
enced a CID after Day 30; in contrast, 67% of patients 
who did not achieve a CII at Week 4 experienced a CID 
after Day 30 (Figure 2A). Similarly, the proportion of 
patients experiencing a CID after Day 30 decreased with 
the increasing number of positive PRO responses at Week 
4 (Figure 2B). The risk of a CID was twice as high in 
patients who did not achieve a CII at Week 4 compared 
with patients who did achieve a CII at Week 4 (Figure 2C).
The proportion of patients experiencing a moderate or 
severe exacerbation after Day 30 was numerically lower in 
patients who achieved a CII at Week 4 compared with 
those who did not achieve a CII at Week 4 (11% vs 14%); 
however, exacerbations were infrequent in this study 
population (Supplementary Figure 2).
Comparison of CII by Treatment
At Week 4, a smaller proportion of patients receiving 
UMEC/VI had 0 or 1 PRO responses (18% and 27%, 
respectively) compared with either UMEC (24% and 
29%) or SAL (22% and 30%); a greater proportion of 
patients receiving UMEC/VI achieved 4 PRO responses 
(11%) compared with UMEC (8%) and SAL (6%).
Table 2 Association Between Patient Demographics and Baseline Characteristics and the Achievement of a CII at Week 4
Characteristic No CII at Week 4 (N=1211) CII at Week 4 (N=1211) P value
Age, years, mean (SD) 64.6 (8.4) 64.6 (8.5) 0.956
Female, n (%) 481 (40) 506 (42) 0.321
Current smoker at screening, n (%) 597 (49) 604 (50) 0.807
Duration of COPD, years, mean (SD) 8.2 (6.4) 8.4 (6.7) 0.408
Baseline rescue medication use, puffs/day, mean 
(SD)
2.0 (2.3) 2.3 (2.6) 0.003
No maintenance medication during run-in, n (%) 328 (27) 421 (35) <0.001
Trough FEV1, mL, mean (SD) 1505 (516) 1476 (518) 0.164
Post-bronchodilator % predicted FEV1, mean 
(SD)
55.5 (13.0) 55.4 (12.5) 0.835
% reversibility to salbutamol, mean (SD) 9.9 (12.7) 11.0 (13.5) 0.037
GADS, n (%)
Mild 235 (19) 175 (14) 0.002a
Moderate 818 (68) 854 (71)
Severe 147 (12) 173 (14)
Very severe 9 (<1) 9 (<1)
GOLD spirometric grade, n (%) – –
1 and 2b 786 (65) 785 (65) 0.966
3 424 (35) 426 (35)
SAC-BDI focal score, mean (SD) 7.1 (1.9) 7.0 (1.8) 0.109
E-RS total score, mean (SD) 10.3 (5.8) 10.9 (5.7) 0.008
CAT score, mean (SD) 18.2 (5.8) 20.2 (6.3) <0.001
SGRQ total score, mean (SD) 42.8 (15.9) 46.6 (16.2) <0.001
Notes: aProportions compared using a Wilcoxon rank sum test; btwo patients in each subgroup were categorized as GOLD grade 1 COPD. 
Abbreviations: CAT, COPD Assessment Test; CII, clinically important improvement; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory 
Symptoms:COPD; FEV1, forced expiratory volume in 1 second; GADS, Global Assessment of Disease Severity; GOLD, Global Initiative for Chronic Obstructive Lung 
Disease; SD, standard deviation; SAC-BDI, self-assessment computerized-Baseline Dyspnea Index; SGRQ, St George’s Respiratory Questionnaire.
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A greater proportion of patients achieved a CII with 
UMEC/VI (56–58%) compared with UMEC (47–52%) and 
SAL (48–49%) at Weeks 4, 12 and 24 (Figure 3). The odds 
of a patient achieving a CII were also significantly greater 
with UMEC/VI versus UMEC and SAL at Weeks 4, 12 and 
24, and the magnitude of the ORs were consistent between 
Weeks 4 and 24 (Figure 3). At Week 24 the NNT (95% CI) 
for CII was 11 (8, 23) for UMEC/VI versus UMEC and 11 
(8, 24) for UMEC/VI versus SAL. In patients who achieved 
a CII with UMEC/VI at Week 4, 72% also achieved a CII at 
Week 24 (Table 5). Similar results were seen with UMEC 
and SAL with 67% and 66%, respectively, achieving a CII at 
both Weeks 4 and 24. Furthermore, with all treatments most 
patients who did not have a CII at Week 4 also did not have 
CII at Week 24 (Table 5).
Discussion
In this post hoc analysis of the EMAX trial, a novel 
composite endpoint of CII requiring concordant MCID 
responses in at least two PRO measures was used to assess 
whether early responses to maintenance bronchodilator 
treatments are associated with longer-term treatment 
responses in symptomatic patients with COPD. When 
compared with patients without a CII at Week 4, patients 
with a CII at Week 4 had 5- and 4-fold greater odds of 
achieving a CII at Weeks 12 and 24, respectively, 
Figure 1 Proportion of patients achieving a CII at Weeks 12 and 24 stratified by 
the achievement of a CII at Week 4. 
Abbreviations: CI, confidence interval; CII, clinically important improvement; OR, 
odds ratio.
Table 3 Ordered OR of GADS Improvement on the 7-Point Likert Scale at Week 4
GADS Response at Week 
4, n (%)
Number of PRO Responsesa at Week 4
No CII at 
Week 4 
(n=1100)
CII at Week 
4 (N=1210)
0 
(n=407)
1 (n=693) 2 (n=579) 3 (n=433) 4 (n=198)
Much Better 17 (2) 85 (7) 2 (<1) 15 (2) 17 (3) 31 (7) 37 (19)
Better 68 (6) 308 (25) 9 (2) 59 (9) 107 (18) 121 (28) 80 (40)
Slightly Better 332 (30) 562 (46) 83 (20) 249 (36) 264 (46) 225 (52) 73 (37)
No Change 509 (46) 215 (18) 213 (52) 296 (43) 158 (27) 50 (12) 7 (4)
Slightly Worse 140 (13) 37 (3) 74 (18) 66 (10) 31 (5) 5 (1) 1 (<1)
Worse 28 (3) 3 (<1) 21 (5) 7 (1) 2 (<1) 1 (<1) 0
Much Worse 6 (<1) 0 5 (1) 1 (<1) 0 0 0
OR of better responseb vs 
no CII (95% CI)
– 5.56 (4.69, 
6.58); p<0.001
– – – – –
OR of better responseb vs 0 
PRO responses (95% CI)
– – – 2.91 (2.30, 
3.69); 
p<0.001
6.67 (5.18, 
8.61); 
p<0.001
15.96 (12.07, 
21.10); 
p<0.001
42.07 (29.58, 
59.83); 
p<0.001
Notes: aA PRO response was defined as meeting the MCID for SAC-TDI, E-RS, CAT or SGRQ scores; bImprovement in GADS was defined as a patient reporting a GADS 
response of Slightly Better, Better or Much Better at Week 4. 
Abbreviations: CAT, COPD Assessment Test; CI, confidence interval; CII, clinically important improvement; COPD, chronic obstructive pulmonary disease; E-RS, 
Evaluating Respiratory Symptoms:COPD; GADS, Global Assessment of Disease Severity; MCID, minimal clinically important difference; OR, odds ratio; PRO, patient- 
reported outcome; SAC-TDI, self-administered computerized-Transition Dyspnea Index; SGRQ, St George’s Respiratory Questionnaire.
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suggesting that patients with early treatment responses had 
greater odds of maintaining their response over a longer 
period of time. Additionally, a lower proportion of patients 
with a CII at Week 4 had a CID after Day 30 compared 
with patients without a CII at Week 4. These data suggest 
that a positive treatment response in CII as early as Week 4 
is associated with greater odds of symptom improvements 
and a reduced likelihood of deterioration at 24 weeks. As 
such, early assessment of treatment response may be 
a useful guide to the likely longer-term benefits of 
a treatment and may facilitate early treatment decisions 
and aid early treatment optimization.
Achieving the composite endpoint of CII at Week 4 
was not associated with fewer subsequent moderate/ 
severe exacerbations, possibly because there were few 
exacerbations during the study as the population had 
a low exacerbation risk. The relatively short study dura-
tion may also have contributed to this. Using an alter-
native definition of CII which included improvement in 
lung function, Kostikas et al demonstrated that in patients 
with a history of exacerbations there was only a weak 
association between CII and future exacerbation risk.12 
Other studies have also shown conflicting evidence 
regarding the association of symptoms with the future 
risk of an exacerbation; for example, worse breathless-
ness according to the modified Medical Research Council 
score has been shown to be associated with an increased 
risk of an exacerbation whereas 24-hour COPD symp-
toms have been found not to be associated with exacer-
bation risk.19,20
The Global Initiative for Chronic Obstructive Lung 
Disease strategy report suggests that regular monitoring 
of changes in symptoms and health status is important to 
measure treatment response,5 therefore, four PROs were 
selected to form the CII endpoint in this study to enable 
a comprehensive assessment of patient benefit. To further 
investigate the potential use of the CII it will be important 
to assess the contribution each PRO makes to the prog-
nostic ability of the endpoint. The present data suggest that 
the responder status of the CAT, SAC-TDI, SGRQ and 
E-RS are not interchangeable, as patients often achieved a 
MCID in only one or two of them. In fact, these PROs 
likely reflect different dimensions of COPD, as suggested 
by the low correlation between some of the measures. 
Although the correlation between CAT and SGRQ scores 
is typically quite high (convergent validity using Pearson’s 
correlation coefficient: 0.69–0.82),21 a one unit difference 
in score (equivalent to 1% change in SGRQ total score and 
<3% change in CAT total score) can result in a different 
responder status for a patient. There was a higher concor-
dance between responder rates with certain combinations 
of PROs compared with others; for example, 27% of the 
patients achieved a CII that included responses to both 
SGRQ and CAT, whereas 14% achieved a CII that 
included responses to both SGRQ and E-RS. 
Accordingly, a post hoc analysis of the 12-week 
CRYSTAL study, which, similar to this study had 
a population of patients at low exacerbation risk, reported 
a similarly weak association between responders to differ-
ent PRO measures.22 Indeed, the CRYSTAL study found 
that 64% of the patients were responders to at least one 
PRO and 33% were responders to at least two PROs,22 
Table 4 Combinations of PRO Responses at Week 4 by 
Treatment
Positive PRO Responses, 
n (%)
UMEC/VI 
(N=812)
UMEC 
(N=804)
SAL 
(N=809)
0 PROs 146 (18) 194 (24) 174 (22)
1 PRO 219 (27) 235 (29) 246 (30)
CAT score 81 (10) 102 (13) 119 (15)
SAC-TDI 65 (8) 64 (8) 67 (8)
SGRQ total score 45 (6) 47 (6) 39 (5)
E-RS total score 28 (3) 22 (3) 21 (3)
2 PROs 210 (26) 172 (21) 198 (24)
SGRQ + CAT 57 (7) 50 (6) 64 (8)
SAC-TDI + CAT 66 (8) 46 (6) 52 (6)
SGRQ + SAC-TDI 34 (4) 28 (3) 36 (4)
SAC-TDI + E-RS 26 (3) 20 (2) 18 (2)
CAT+ E-RS 18 (2) 20 (2) 23 (3)
SGRQ + E-RS 9 (1) 8 (<1) 5 (<1)
3 PROs 150 (18) 140 (17) 143 (18)
SGRQ + SAC-TDI + CAT 82 (10) 71 (9) 70 (9)
SAC-TDI + CAT + E-RS 28 (3) 35 (4) 25 (3)
SGRQ + CAT + E-RS 18 (2) 19 (2) 31 (4)
SGRQ + SAC-TDI + E-RS 22 (3) 15 (2) 17 (2)
4 PROs
SGRQ + SAC-TDI + 
CAT + E-RS
87 (11) 63 (8) 48 (6)
No CII achieved (0 or 1 
PRO)
365 (45) 429 (53) 420 (52)
CII achieved (2, 3 or 4 
PROs)
447 (55) 375 (47) 389 (48)
Abbreviations: CAT, COPD Assessment Test; CII, clinically important improve-
ment; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory 
Symptoms:COPD; PRO, patient-reported outcome; SAC TDI, self-administered 
computerized-Transition Dyspnea Index; SAL, salmeterol; SGRQ, St George’s 
Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.
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similar to the 79% and 50%, respectively, achieving these 
outcomes at Week 4 in the current study. This supports the 
hypothesis that when using a responder analysis approach, 
the use of a composite endpoint such as the CII may be 
a more reliable tool for detecting a broader range of 
improvements in symptoms and health status than the 
monitoring of single individual subjective PRO.
In clinical practice, it is time-consuming and impractical 
to monitor several different PRO measures; however, the 
CII may be a useful endpoint in clinical trials as 
Figure 2 Proportion of patients with a Clinically Important Deterioration (CID)a after Day 30 by: (A) achievement of a CII at Week 4; (B) the number of PRO responses at 
Week 4; (C) Kaplan–Meier curve of time to first CID in patients by achievement of CII at Week 4. 
Notes: aA CID was defined as a first moderate or severe exacerbation, and/or a SGRQ deterioration (≥4 units from baseline), and/or a CAT deterioration (≥2 units from 
baseline), and/or a SAC-TDI deterioration (≥1 unit decrease from baseline). 
Abbreviations: CAT, COPD Assessment Test; CID, clinically important deterioration; CI, confidence interval; CII, clinically important improvement; COPD, chronic 
obstructive pulmonary disease; HR, hazard ratio; PRO, patient-reported outcome; SAC-TDI, self-administered computerized-Transition Dyspnea Index; SGRQ, St George’s 
Respiratory Questionnaire.
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achievement of a CII at an early time point may be indica-
tive of longer-term treatment efficacy. In this analysis, con-
sistent treatment differences in CII were observed between 
UMEC/VI and both monotherapies as early as Week 4, with 
a CII experienced by a significantly greater proportion of 
patients treated with UMEC/VI (56%) versus UMEC (47%) 
and SAL (48%). These treatment differences were main-
tained or slightly increased throughout the 24-week study 
period. As all bronchodilator classes performed consistently 
throughout the study period, this suggests that treatment 
success with LAMA/LABA, LAMA and LABA can be 
evaluated as early as 4 weeks after treatment initiation 
using the CII endpoint. In addition, the greater proportion 
of patients achieving CII with UMEC/VI compared with 
monotherapy provides further evidence of treatment bene-
fits of dual bronchodilator therapy.
There are potential limitations to consider when interpret-
ing this analysis. It was a post hoc analysis of the EMAX trial, 
in which the outcomes were only measured for up to 24 weeks; 
prospective and longer-term analyses are required to further 
investigate the CII. However, as COPD is a progressive dis-
ease, necessitating treatment augmentation with time, the need 
for long-term studies must be balanced against the need for 
therapeutic pragmatism in designing trials. This was an analy-
sis of a randomized control trial; analyses of real-world data are 
also required to investigate the potential relevance of these 
findings to clinical practice. Furthermore, compared with 
patients who did not have a CII at Week 4, patients who 
Figure 3 Proportion of patients achieving CII (reaching MCID in at least two PROs) at Weeks 4, 12 and 24a. 
Notes: aAnalysis of patients with a responder status for ≥2 PROs at each visit. 
Abbreviations: CI, confidence interval; CII, clinically important improvement; MCID, minimum clinically important difference; OR, odds radio; PRO, patient-reported 
outcome; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol.
Table 5 Proportion of Patients Who Maintained Their Week 4 CII Status at Week 24
Patients Who Achieved CII at Week 4
UMEC/VI (n=447) UMEC (n=375) SAL (n=389)
Patients who achieved CII at Week 24, n (%) 322 (72) 250 (67) 255 (66)
Patients who did not achieve CII at Week 24, n (%) 125 (28) 125 (33) 134 (34)
Patients without CII response at Week 4
UMEC/VI (n=362) UMEC (n=423) SAL (n=416)
Patients who achieved CII at Week 24, n (%) 135 (37) 132 (31) 133 (32)
Patients who did not achieve CII at Week 24, n (%) 227 (63) 291 (69) 283 (68)
Notes: The proportion of patients who maintained their Week 4 CII status at Week 24 is shown in bold. 
Abbreviations: CII, clinically important improvement; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol.
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achieved a CII at Week 4 had significantly worse E-RS, CAT 
and SGRQ scores at baseline, therefore regression to the mean 
effect may have affected the results. Also, factors such as 
change in smoking status during the study, patient comorbid-
ities, treatment adherence and device errors have not been 
considered in this analysis. Finally, these data must be inter-
preted in the context of the EMAX patient population, which 
consisted of symptomatic patients with a low exacerbation risk 
who were not receiving ICS nor had prior use of combination 
maintenance therapies. However, this is an important popula-
tion for the analysis of CII and provides new information to 
complement the analysis of a CII endpoint in the FLAME 
study, where the population had a history of exacerbations 
and prior use of combination therapy.12
Conclusion
The results of this post hoc analysis suggest that achieving 
a clinically significant improvement in two or more PROs after 
4 weeks of treatment is associated with longer-term improve-
ments in symptom severity and health status and is associated 
with a reduced incidence of future CID than achieving a single 
or no positive PRO responses. This suggests that response to 
treatment could be assessed soon after treatment initiation and 
provides further evidence of the importance of early treatment 
optimization. In a complex chronic and progressive disease 
like COPD, no consensus exists on what constitutes treatment 
success; these preliminary findings suggest further research 
may be warranted to address the importance of achieving 
concordant patient-centric responses.
Abbreviations
BDI, Baseline Dyspnea Index; CAT, COPD Assessment 
Test; CI, confidence interval; CID, clinically important 
deterioration; CII, clinically important improvement; 
COPD, chronic obstructive pulmonary disease; EMAX, 
Early MAXimization of bronchodilation for improving 
COPD stability; E-RS, Evaluating Respiratory 
Symptoms:COPD; FEV1, forced expiratory volume in 
1 second; FVC, forced vital capacity; GADS, Global 
Assessment of Disease Severity; GOLD, Global Initiative 
for Chronic Obstructive Lung Disease; HR, hazard ratio; 
ICS, inhaled corticosteroid; IEC, independent ethics com-
mittee; IRB, institutional review board; ITT, intent-to- 
treat; LABA, long-acting β2-agonist; LAMA, long-acting 
muscarinic antagonist; MCID, minimum clinically impor-
tant differences; NNT, number needed to treat; OR, odds 
ratio; PRO, patient-reported outcome; SAC-TDI, self- 
administered computerized-Transition Dyspnea Index; 
SAL, salmeterol; SD, standard deviation; SGRQ, St 
George’s Respiratory Questionnaire; TDI, Transition 
Dyspnea Index; UMEC, umeclidinium; VI, vilanterol.
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